Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Mereo BioPharma (MREO) EBT (2023 - 2025)

Mereo BioPharma (MREO) has disclosed EBT for 3 consecutive years, with -$7.0 million as the latest value for Q3 2025.

  • On a quarterly basis, EBT rose 53.18% to -$7.0 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$41.6 million, a 9.32% increase, with the full-year FY2024 number at -$43.3 million, down 44.19% from a year prior.
  • EBT was -$7.0 million for Q3 2025 at Mereo BioPharma, up from -$14.6 million in the prior quarter.
  • In the past five years, EBT ranged from a high of -$1.8 million in Q2 2023 to a low of -$15.0 million in Q3 2024.
  • A 3-year average of -$9.8 million and a median of -$9.6 million in 2023 define the central range for EBT.
  • Peak YoY movement for EBT: tumbled 599.89% in 2024, then soared 53.18% in 2025.
  • Mereo BioPharma's EBT stood at -$9.6 million in 2023, then rose by 26.91% to -$7.0 million in 2024, then grew by 0.31% to -$7.0 million in 2025.
  • Per Business Quant, the three most recent readings for MREO's EBT are -$7.0 million (Q3 2025), -$14.6 million (Q2 2025), and -$12.9 million (Q1 2025).